Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Sharon Bender

Recent Posts

Trends That Matter for New Multiple Sclerosis Value-Based Contract

Posted by Sharon Bender on Jan 16, 2020

Under a value-based contracting agreement believed to be the first of its kind, UPMC Health Plan will receive discounts for two Biogen Inc. multiple sclerosis (MS) drugs — Tecfidera (dimethyl fumarate) and Avonex (interferon beta-1a) — based on patient-reported measures of disability progression. The agreement is also based on research with a panel of key MS stakeholders who identified the most meaningful outcomes in relapsing forms of MS, AIS Health reported.

UPMC's Center for Value-Based Pharmacy Initiatives led the research and developed the value-based contract.
 
Read More

Topics: Industry Trends, Market Access, Data & Analytics

Radar On Market Access: Patient-Reported Outcomes Play Key Role in New Multiple Sclerosis Value-Based Contract

Posted by Sharon Bender on Dec 19, 2019

Under a value-based contracting agreement believed to be the first of its kind, UPMC Health Plan will receive discounts for two Biogen Inc. multiple sclerosis (MS) drugs — Tecfidera (dimethyl fumarate) and Avonex (interferon beta-1a) — based on patient-reported measures of disability progression. The agreement is also based on research with a panel of key MS stakeholders who identified the most meaningful outcomes in relapsing forms of MS, AIS Health reported.

UPMC's Center for Value-Based Pharmacy Initiatives led the research and developed the value-based contract.

Read More

Topics: Specialty, Market Access, Data & Analytics, Provider, Payer